Tokyo Tape
Sign in
← ASKA Pharmaceutical Holdings

Quarterly report · Q1

4886.TEDINET S100OVV1
Period2022-04-01 → 2022-06-30
Filed2022-08-08
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
MetricValuePeriodScopeSource row
Revenue¥15.3bn2022-04-01 → 2022-06-30Cons.Net sales
Revenue¥56.6bn2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥14.2bn2021-04-01 → 2021-06-30Cons.Net sales
Operating income¥1.7bn2022-04-01 → 2022-06-30Cons.Operating income
Operating income¥1.2bn2021-04-01 → 2021-06-30Cons.Operating income
Ordinary income¥1.8bn2022-04-01 → 2022-06-30Cons.Ordinary income
Ordinary income¥4.9bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥1.3bn2021-04-01 → 2021-06-30Cons.Ordinary income
Profit before tax¥1.8bn2022-04-01 → 2022-06-30Cons.Income before income taxes
Profit before tax¥1.3bn2021-04-01 → 2021-06-30Cons.Income before income taxes
Net income (owners)¥1.3bn2022-04-01 → 2022-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥4.3bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥1.1bn2021-04-01 → 2021-06-30Cons.Profit loss attributable to owners of parent
Net income¥1.3bn2022-04-01 → 2022-06-30Cons.Profit loss
Net income¥1.1bn2021-04-01 → 2021-06-30Cons.Profit loss
Total assets¥84.8bnat 2022-06-30Cons.Assets
Total assets¥83.3bnat 2022-03-31Cons.Assets
Total assets¥81.7bnat 2021-06-30Cons.Total assets (5-year summary)
Total liabilities¥34.3bnat 2022-06-30Cons.Liabilities
Total liabilities¥34.4bnat 2022-03-31Cons.Liabilities
Net assets / equity¥50.5bnat 2022-06-30Cons.Net assets
Net assets / equity¥48.9bnat 2022-03-31Cons.Net assets
Net assets / equity¥45.3bnat 2021-06-30Cons.Net assets (5-year summary)
Cash and deposits¥17.7bnat 2022-06-30Cons.Cash and deposits
Cash and deposits¥12.1bnat 2022-03-31Cons.Cash and deposits
EPS (basic)¥46.942022-04-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥151.222021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥38.722021-04-01 → 2021-06-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio59.6%at 2022-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio58.7%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio55.5%at 2021-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 34
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2022-06-30¥44m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2022-06-30¥29m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2022-06-30¥15m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2022-06-30−¥18m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-06-30−¥15m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-06-30−¥15m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-06-30−¥169m
jpcrp040300-q1r_E35791-000Animal Health Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥1.6bn
jpcrp040300-q1r_E35791-000Animal Health Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥1.6bn
jpcrp040300-q1r_E35791-000Animal Health Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥124m
jpcrp040300-q1r_E35791-000Pharmaceutical Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥13.6bn
jpcrp040300-q1r_E35791-000Pharmaceutical Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥13.6bn
jpcrp040300-q1r_E35791-000Pharmaceutical Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥1.7bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-06-30¥15.3bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-06-30¥15.3bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-06-30¥15m
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-06-30¥1.8bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2021-04-01 → 2021-06-30¥42m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2021-04-01 → 2021-06-30¥30m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2021-04-01 → 2021-06-30¥12m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2021-04-01 → 2021-06-30−¥2m
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-06-30−¥12m
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-06-30−¥12m
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-06-30−¥160m
jpcrp040300-q1r_E35791-000Animal Health Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥1.4bn
jpcrp040300-q1r_E35791-000Animal Health Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥1.4bn
jpcrp040300-q1r_E35791-000Animal Health Businessreportable segmentsegment profit2021-04-01 → 2021-06-30¥103m
jpcrp040300-q1r_E35791-000Pharmaceutical Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥12.8bn
jpcrp040300-q1r_E35791-000Pharmaceutical Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥12.8bn
jpcrp040300-q1r_E35791-000Pharmaceutical Businessreportable segmentsegment profit2021-04-01 → 2021-06-30¥1.2bn
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-06-30¥14.2bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-06-30¥14.2bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-06-30¥12m
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-06-30¥1.3bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 325
ItemContextValueUnit
Other noiCurrentYTDDuration34000000JPY
Non operating incomePrior1YTDDuration234000000JPY
Non operating incomeCurrentYTDDuration212000000JPY
Interest expenses noePrior1YTDDuration14000000JPY
Interest expenses noeCurrentYTDDuration13000000JPY
Foreign exchange losses noePrior1YTDDuration6000000JPY
Foreign exchange losses noeCurrentYTDDuration20000000JPY
Other noePrior1YTDDuration71000000JPY
Other noeCurrentYTDDuration37000000JPY
Non operating expensesPrior1YTDDuration92000000JPY
Non operating expensesCurrentYTDDuration71000000JPY
Ordinary incomePrior1YTDDuration1329000000JPY
Ordinary incomeCurrentYTDDuration1805000000JPY
Income before income taxesPrior1YTDDuration1329000000JPY
Income before income taxesCurrentYTDDuration1805000000JPY
Income taxes currentPrior1YTDDuration165000000JPY
Income taxes currentCurrentYTDDuration199000000JPY
Income taxes deferredPrior1YTDDuration65000000JPY
Income taxes deferredCurrentYTDDuration283000000JPY
Income taxesPrior1YTDDuration230000000JPY
Income taxesCurrentYTDDuration482000000JPY
Profit lossPrior1YTDDuration1098000000JPY
Profit lossCurrentYTDDuration1323000000JPY
Profit loss attributable to owners of parentPrior1YTDDuration1098000000JPY
Profit loss attributable to owners of parentCurrentYTDDuration1323000000JPY
Profit lossPrior1YTDDuration1098000000JPY
Profit lossCurrentYTDDuration1323000000JPY
Valuation difference on available for sale securities net of tax ociPrior1YTDDuration-35000000JPY
Valuation difference on available for sale securities net of tax ociCurrentYTDDuration323000000JPY
Remeasurements of defined benefit plans net of tax ociPrior1YTDDuration7000000JPY
Remeasurements of defined benefit plans net of tax ociCurrentYTDDuration6000000JPY
Share of other comprehensive income of associates accounted for using equity method ociPrior1YTDDuration-84000000JPY
Share of other comprehensive income of associates accounted for using equity method ociCurrentYTDDuration139000000JPY
Other comprehensive incomePrior1YTDDuration-112000000JPY
Other comprehensive incomeCurrentYTDDuration469000000JPY
Comprehensive incomePrior1YTDDuration986000000JPY
Comprehensive incomeCurrentYTDDuration1792000000JPY
Comprehensive income attributable to owners of the parentPrior1YTDDuration986000000JPY
Comprehensive income attributable to owners of the parentCurrentYTDDuration1792000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q1r_E35791-000PharmaceuticalBusinessReportableSegmentsMember12840000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q1r_E35791-000AnimalHealthBusinessReportableSegmentsMember1351000000JPY
Revenues from external customersPrior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember30000000JPY
Revenues from external customersPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember14221000000JPY
Revenues from external customersPrior1YTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersPrior1YTDDuration14221000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q1r_E35791-000PharmaceuticalBusinessReportableSegmentsMember－JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q1r_E35791-000AnimalHealthBusinessReportableSegmentsMember－JPY
Transactions with other segmentsPrior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember12000000JPY
Transactions with other segmentsPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember12000000JPY
Transactions with other segmentsPrior1YTDDuration_ReconcilingItemsMember-12000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identityconsolidated 2022-06-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-06-30pass